Alnylam Pharmaceuticals (ALNY) News Today

Alnylam Pharmaceuticals (ALNY) — The stock is trading higher today amid analyst support and momentum headlines, but sentiment is mixed because Leerink/Leerink Partnrs has cut near-term EPS estimates and issued more cautious guidance. Investors are likely reacting to the Truist price‑target lift and a fresh 52‑week high while weighing Leerink's downward revisions ahead of Alnylam's Q3 webcast.

• Positive Sentiment: Truist raised its price target to $535 and reiterated a "buy" rating, signaling analyst conviction and ~11% implied upside from current levels — a catalyst underpinning the rally. Truist Raises Price Target to $535
• Positive Sentiment: Technical momentum: coverage noted ALNY hit a new 52‑week high, which can attract momentum and ETF flows. ALNY Hits New 52-Week High
• Positive Sentiment: Analysts and press are re‑assessing valuation after reports of new partnerships, pipeline progress and fresh financing — narrative that supports a higher valuation multiple if execution continues. Assessing Valuation Following New Partnerships
• Neutral Sentiment: Alnylam scheduled a webcast to discuss Q3 2025 results — a near‑term event that will drive volatility and give clarity on revenue/guidance vs. recent analyst revisions. Q3 2025 Webcast
• Neutral Sentiment: Coverage pieces summarizing Leerink's forecasts (FY2026 discussions) are circulating — useful for investors but not new company data. Leerink FY2026 Forecast Summary
• Negative Sentiment: Leerink/Leerink Partnrs cut near‑term EPS estimates sharply (Q3 down from $0.38 to $0.03) and lowered FY2025 EPS (to about -$0.10), flagging weaker near‑term earnings outlook that could pressure the stock if confirmed. Leerink Lowers EPS Estimates
• Negative Sentiment: Leerink reportedly moved to a "hold" view in coverage (coverage note highlighted by press) — a more cautious stance that can limit upside from investor flows even with positive headlines. Leerink Issues Hold

Bottom line for investors: upside today is driven by the Truist upgrade, valuation/pipeline optimism and technical strength; watch the Q3 webcast and Leerink's lowered near‑term EPS assumptions for confirmation — those items are the most likely near‑term drivers of further moves in ALNY.